Back to Search
Start Over
Long-Term Follow-Up of Patients with Scleritis After Rituximab Treatment Including B Cell Monitoring
- Source :
- van Bilsen , K , Vergouwen , D P C , van Velthoven , M E J , Missotten , T O A R , Rombach , S M , van Zelm , M C , Berkowska , M A , van Hagen , P M , Kuijpers , R W A M & van Laar , J A M 2023 , ' Long-Term Follow-Up of Patients with Scleritis After Rituximab Treatment Including B Cell Monitoring ' , Ocular Immunology and Inflammation .
- Publication Year :
- 2023
-
Abstract
- Purpose: We report the long-term effect of rituximab (RTX) in scleritis and determine the value of B-cell monitoring for the prediction of relapses. Methods: We retrospectively studied 10 patients with scleritis, who were treated with RTX. Clinical characteristics were collected, and blood B-cell counts were measured before the start of RTX, and at various time points after treatment. Results:Clinical activity of scleritis decreased after RTX treatment in all patients within a median time of 8 weeks (range 3–13), and all reached remission. The median follow-up was 101 months (range 9–138). Relapses occurred in 6 out of 10 patients. All relapses, where B-cell counts were measured (11 out of 19), were heralded by returning B cells. However, B cells also returned in patients with long-term remissions.Conclusions: RTX is a promising therapeutic option for scleritis. Recurrence of B cells after initial depletion does not always predict relapse of scleritis.
Details
- Database :
- OAIster
- Journal :
- van Bilsen , K , Vergouwen , D P C , van Velthoven , M E J , Missotten , T O A R , Rombach , S M , van Zelm , M C , Berkowska , M A , van Hagen , P M , Kuijpers , R W A M & van Laar , J A M 2023 , ' Long-Term Follow-Up of Patients with Scleritis After Rituximab Treatment Including B Cell Monitoring ' , Ocular Immunology and Inflammation .
- Notes :
- application/pdf, English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1398451799
- Document Type :
- Electronic Resource